Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20089 in Advanced Solid Tumors
NCT05263479Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mocertatug rezetecan in solid tumor (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at 3 weeks. Started Jan 2022; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05263479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263479.